SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Top Headlines

J&J to increase wearable insulin patch-pump production

Johnson & Johnson will scale up manufacturing of a three-day wearable patch pump used to deliver insulin, in preparation for a post 2015 launch.

Allergan axing a further 577 at Cali HQ, post-Actavis acquisition

Almost 600 staff at Allergan’s headquarters in Irvine, California, will be laid off in the Botox maker’s latest round of job cuts.

Anti-fungal shows promise for cancer breakthrough in preclinical tests

An anti-fungal drug shows potential to treat a range of cancers, according to research from the Repurposing Drugs in Oncology (ReDO) project.

‘We must not rest on our laurels’

GEA revenue growth for 2015 overshadowed by 1,450 job cuts

GEA said it expects to achieve a moderate organic growth in revenue and an operating EBITDA of between €580 and €620m in the current fiscal year 2015, but its growth is overshadowed by 1,450 job cuts.

EDQM seeks industry input on water for injection monograph revision

The EDQM is revising its water for injection (WFI) monograph to accomodate cheaper and greener alternatives to distillation and has called on injectable drugmakers to contribute.

Spotlight

'Unjustified' ban of GVK-tested drugs has damaged India, Pharmexcil

'Unjustified' ban of GVK-tested drugs has damaged India, says Pharmexcil

The reputation of Indian clinical trials has been damaged by the “unjustified” suspension of medicines tested by...

Calling all QA/QC whizzes: US FDA 'super' office hunts quality leader

Calling all QA/QC whizzes: US FDA 'super' office hunts quality leader

The Director of the new 'super' Office of Pharmaceutical Quality must address issues surrounding increasing globalisation and...

Pfizer pulls vaccine sales out of China after Prevenar import ban

Pfizer pulls vaccine sales out of China after Prevenar import ban

Pfizer says it will stop selling vaccines in China after the country denied an import licence for...

Sanofi: 80% of population ignored as pharma cash focuses on orphan R&D

Sanofi: 80% of population ignored as pharma targets lower-risk specialty R&D

Pharma has focused investment in lower risk specialty and orphan diseases to the detriment of 80% of...

FDA looks to incentivize abuse-deterrent opioid development with final guidance

FDA looks to incentivize abuse-deterrent opioid development with final guidance

Although the abuse-deterrent technology is still relatively new, the FDA has released final guidance explaining to manufacturers...

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...